Sharp-Header

Sharp-Header

X

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Reset Filter

All Drugs in Dev.

Product Type

Companies

AM-Pharma

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Food & Nutrition Conference & Expo

Participation Not Confirmed

Update your Virtual Booth

AM-Pharma Increases Funding To €163m For Phase-Iii Trial Of Recap In Sa-Aki

Lead Product(s): Recombinant Alkaline Phosphatase

Therapeutic Area: Nephrology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Cowen Healthcare Investments

Deal Size: $52.0 million Upfront Cash: Undisclosed

Deal Type: Funding March 31, 2020

Details:

New capital to be used to support a multi-national pivotal Phase III trial of recAP in 1,400 patients with sepsis-associated-acute kidney injury (SA-AKI).